Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.87% is 71% above its 5-year average of 58.40%, near the high end of its 5-year range (-219.90%–100.00%).
71.93% above its 12-month average of 58.09%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
99.87%
GROSS MARGIN AVG TTM
58.09%
GROSS MARGIN AVG 3Y
99.94%
GROSS MARGIN AVG 5Y
58.40%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+71.93%
CURRENT VS 3Y AVG
-0.07%
CURRENT VS 5Y AVG
+71.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+142.37%
vs the sector median at left
Opus Genetics, Inc.
Market Cap
$361.64M
Gross Margin
99.87%
TTM Avg
58.09%
3Y Avg
99.94%
5Y Avg
58.40%
Market Cap
$359.53M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$355.43M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$355.36M
Gross Margin
57.21%
TTM Avg
58.46%
3Y Avg
59.89%
5Y Avg
60.54%
Market Cap
$353.88M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$369.50M
Gross Margin
95.50%
TTM Avg
97.75%
3Y Avg
98.88%
5Y Avg
1.50%
Market Cap
$349.70M
Gross Margin
99.32%
TTM Avg
95.85%
3Y Avg
93.96%
5Y Avg
99.79%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $361.64M | 99.87% | 58.09% | 99.94% | 58.40% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 93.73% | 92.44% | 93.34% | 78.89% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 0.00% | 50.00% | 75.00% | 66.67% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 57.21% | 58.46% | 59.89% | 60.54% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 98.15% | 96.49% | 98.25% | 98.83% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | 95.50% | 97.75% | 98.88% | 1.50% |
| Embecta Corp. (EMBC)vs › | $353.00M | 59.89% | 63.90% | 65.83% | 67.05% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | 45.86% | 48.66% | 71.42% | -2398.51% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 99.32% | 95.85% | 93.96% | 99.79% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | 0.00% | 0.00% | 25.00% | 40.00% |
Gross Margin
99.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 99.40% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | -108.95% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | -80.80% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | -177.82% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | -219.90% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
